|
C15ORF29 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.673500000001E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.211600E-04 |
| Normal-vs-Stage2 |
3.57060000000242E-05 |
| Normal-vs-Stage3 |
8.06180000000323E-05 |
| Normal-vs-Stage4 |
5.173800E-04 |
| Stage1-vs-Stage2 |
6.283700E-02 |
| Stage1-vs-Stage3 |
2.458600E-01 |
| Stage1-vs-Stage4 |
2.919800E-01 |
| Stage2-vs-Stage3 |
3.911800E-01 |
| Stage2-vs-Stage4 |
5.507800E-01 |
| Stage3-vs-Stage4 |
8.801400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.1454999999988E-05 |
| Normal-vs-AfricanAmerican |
1.004200E-01 |
| Normal-vs-Asian |
4.228300E-02 |
| Caucasian-vs-AfricanAmerican |
3.233400E-01 |
| Caucasian-vs-Asian |
1.822790E-01 |
| AfricanAmerican-vs-Asian |
9.958200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.432800E-04 |
| Normal-vs-Female |
2.48619999999589E-05 |
| Male-vs-Female |
6.366400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.375500E-04 |
| Normal-vs-Age(41-60Yrs) |
8.26690000000907E-05 |
| Normal-vs-Age(61-80Yrs) |
9.57259999999627E-05 |
| Normal-vs-Age(81-100Yrs) |
5.682500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.660200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.335240E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.113000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.298000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.939000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.175600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.608200E-02 |
| Classical-VS-Follicular |
1.440360E-02 |
| Classical-VS-Other |
7.610600E-01 |
| Classical-VS-Normal |
1.315380E-03 |
| Tall-VS-Follicular |
9.919800E-01 |
| Tall-VS-Other |
2.162200E-01 |
| Tall-VS-Normal |
2.013000E-04 |
| Follicular-VS-Other |
3.063800E-01 |
| Follicular-VS-Normal |
4.00630000000346E-05 |
| Other-VS-Normal |
3.442600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.55310000002651E-06 |
| Normal-vs-N1 |
3.356100E-02 |
| N0-vs-N1 |
1.100800E-01 |
|
|
